Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer

European Journal of Cancer

Volumn 44, Issue 9, 2008, Pages 1229-1237

  Martinez Balibrea, Eva ^a   Abad, Albert ^a   Aranda, Enrique ^b   Sastre, Javier ^c   Manzano, Jose Luis ^a   Díaz Rubio, Eduardo ^c   Gómez España, Auxiliadora ^b   Aparicio, Jorge ^d   García, Teresa ^e   Maestu, Inmaculada ^f   Martínez Cardús, Anna ^a   Ginés, Alba ^a   Guino, Elisabet ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL MORALES MESEGUER   (Spain)

^f HOSPITAL VIRGEN DE LOS LIRIOS   (Spain)

Author keywords

5FU; Advanced colorectal cancer; Capecitabine; ERCC1 118; Oxaliplatin; Polymorphisms; TS 3'UTR

Indexed keywords

CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; OXALIPLATIN;

ADULT; ADVANCED CANCER; ARTICLE; CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CORRELATION ANALYSIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; ERCC1 GENE; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARAMETER; PHARMACOGENETICS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; SURVIVAL; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; UNTRANSLATED REGION; VOMITING; XRCC1 GENE; XRCC3 GENE;

ADULT; AGED; ALLELES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; GENOTYPE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PATIENT SELECTION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 44449170247     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.03.025     Document Type: Article

References (33)

1. Braun A.H., Achterrath W., Wilke H., Vanhoefer U., Harstrick A., and Preusser P. New systemic frontline treatment for metastatic colorectal carcinoma. Cancer 100 8 (2004) 1558-1577
2. Schmoll H.J., and Arnold D. Update on capecitabine in colorectal cancer. Oncologist 11 9 (2006) 1003-1009
3. Porschen R., Arkenau H.T., Kubicka S., et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25 27 (2007) 4217-4223
4. Diaz-Rubio E., Tabernero J., Gomez-Espana A., et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumours Trial. J Clin Oncol 25 27 (2007) 4224-4230
5. Mayer R.J. Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?. J Clin Oncol 25 27 (2007) 4165-4167
6. Quinney S.K., Sanghani S.P., Davis W.I., et al. Hydrolysis of capecitabine to 5'-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. J Pharmacol Exp Ther 313 3 (2005) 1011-1016
7. Takebayashi Y., Yamada K., Miyadera K., et al. The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 32A 7 (1996) 1227-1232
8. Raymond E., Faivre S., Chaney S., Woynarowski J., and Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1 3 (2002) 227-235
9. Dotor E., Cuatrecases M., Martinez-Iniesta M., et al. Tumour thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 24 10 (2006) 1603-1611
10. Marcuello E., Altes A., del Rio E., Cesar A., Menoyo A., and Baiget M. Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 112 5 (2004) 733-737
11. Pullarkat S.T., Stoehlmacher J., Ghaderi V., et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogen J 1 1 (2001) 65-70
12. de las Penas R., Sanchez-Ronco M., Alberola V., et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 17 4 (2006) 668-675
13. Martinez-Balibrea E., Manzano J.L., Martinez-Cardus A., et al. Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan. Oncol Rep 17 3 (2007) 637-645
14. Park D.J., Stoehlmacher J., Zhang W., Tsao-Wei D.D., Groshen S., and Lenz H.J. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61 24 (2001) 8654-8658
15. Viguier J., Boige V., Miquel C., et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumour response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11 17 (2005) 6212-6217
16. Abad A., Carrato A., Navarro M., et al. Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer. Clin Colorectal Cancer 4 6 (2005) 384-389
17. Marsh S. Thymidylate synthase pharmacogenetics. Invest New Drugs 23 6 (2005) 533-537
18. Etienne M.C., Chazal M., Laurent-Puig P., et al. Prognostic value of tumoural thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 20 12 (2002) 2832-2843
19. Kawakami K., Salonga D., Park J.M., et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 7 12 (2001) 4096-4101
20. Ishida Y., Kawakami K., Tanaka Y., Kanehira E., Omura K., and Watanabe G. Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer. Anticancer Res 22 5 (2002) 2805-2809
21. Iacopetta B., Grieu F., Joseph D., and Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85 6 (2001) 827-830
22. Jakobsen A., Nielsen J.N., Gyldenkerne N., and Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 23 7 (2005) 1365-1369
23. Lincz L.F., Scorgie F.E., Garg M.B., and Ackland S.P. Identification of a novel single nucleotide polymorphism in the first tandem repeat sequence of the thymidylate synthase 2R allele. Int J Cancer 120 9 (2007) 1930-1934
24. Mandola M.V., Stoehlmacher J., Zhang W., et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoural TS mRNA levels. Pharmacogenetics 14 5 (2004) 319-327
25. Popat S., Matakidou A., and Houlston R.S. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22 3 (2004) 529-536
26. Ulrich C.M., Bigler J., Bostick R., Fosdick L., and Potter J.D. Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas. Cancer Res 62 12 (2002) 3361-3364
27. Yu J.J., Lee K.B., Mu C., et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 16 3 (2000) 555-560
28. Plasencia C, Taron M, Martinez-Balibrea E, Rosell R, Abad A. Down regulation of thymidylate synthase gene expression after oxaliplatin administration: implication for the synergistic activity of sequential Oxaliplatin/5FU in sensitive and 5FU-resistant cell lines. American Asociation for Cancer Research (AACR) (New Orleans, LA). In: AACR Proceedings, vol. 42; 2001. p. 2735.
29. Carlini L.E., Meropol N.J., Bever J., et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11 3 (2005) 1226-1236
30. Tsuji T., Hidaka S., Sawai T., et al. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumour sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res 9 10 Pt 1 (2003) 3700-3704
31. Meropol N.J., Gold P.J., Diasio R.B., et al. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24 25 (2006) 4069-4077
32. Metzger R., Danenberg K., Leichman C.G., et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumours is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 4 10 (1998) 2371-2376
33. Cobo M., Isla D., Massuti B., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25 19 (2007) 2747-2754